IXHL Well Will You Look At That?

$IXHL Incannex Healthcare Inc.

Detailed Trading & Company Notes
As of March 25, 2026 (Post-Market)

---

1. 📊 Today's Price Action & Technical Snapshot

• Intraday Range: $2.80 – $3.45
• Current / Last Trade: ~$3.00 – $3.30 (≈ +12–20% intraday depending on timing)
• Previous Close (Mar 24): ~$2.78 – $2.89
• Volume: Significantly elevated (hundreds of thousands to ~1M shares)
• Market Cap: ~$33M – $47M (micro-cap)
• 52-Week Range: $2.40 – $49.80 (extreme volatility; reverse splits & dilution impact)

Short-term Turnaround Attempt:
Price is reacting positively to today’s AASM Foundation partnership news while bouncing from recent lows.

What matters next: Watch for sustained volume and a hold above $3.50 for continuation.

---

2. 🧬 Company Overview

Incannex Healthcare Inc. (NASDAQ: IXHL) is a clinical-stage biopharmaceutical company focused on developing innovative combination therapies, primarily involving cannabinoid and psychedelic compounds.

Lead Program: IHL-42X — an oral fixed-dose combination of dronabinol + acetazolamide targeting Obstructive Sleep Apnea (OSA).

Additional pipeline includes:

• PSX-001 (psilocybin-based) for generalized anxiety disorder
• Programs targeting inflammatory conditions

---

3. 🚀 Recent Positive Catalysts (March 2026)

March 25, 2026 — AASM Foundation Partnership
Collaboration supporting a 2026 sleep apnea research grant. Direct alignment with IHL-42X development.

March 18, 2026 — Balance Sheet Strength
~$75M cash, zero debt. Runway projected into 2027. Notably trading near or below cash-adjusted valuation.

March 17, 2026 — Nasdaq Compliance Regained
Met minimum bid requirement ($1.00+ for 11 consecutive days), removing listing overhang.

March 12, 2026 — $10M Registered Direct Offering
Priced at $5.00/share + warrants. Funding Phase 2 DReAMzz study. ATM facility terminated (shift toward structured raises).

Additional Tailwind: FDA Fast Track designation for IHL-42X (late 2025), supported by strong Phase 2 data (AHI reduction + safety profile).

---

4. 📣 Sentiment on X (Selected Trading Accounts)

From your tracked accounts:

• Only @ACInvestorBlog posted about $IXHL recently (December 2025 timeframe)
• Described as a lesser-known cannabis/biotech setup
• Highlighted rounding bottom and descending trendline break at the time
• Framed as a potential breakout candidate if resistance cleared

No recent March 2026 posts from other tracked accounts (e.g., @Ultra_Calls, @MrZackMorris, @Biotech_SD, etc.).

Broader sentiment today (March 25):

• Light chatter tied to AASM partnership news
• Technical commentary (cup/handle interpretations, accumulation zones)
• Appearing in multi-ticker watchlists
• No major influencer-driven hype or coordinated push

Conclusion: Current move appears news + technical driven, not sentiment-driven.

---

5. ⚠️ Key Risks & Considerations

• Clinical-stage biotech risk (uncertain trial outcomes)
• Phase 2 → Phase 3 execution risk
• History of dilution and reverse splits
• No revenue or profitability yet
• Micro-cap liquidity risk (sharp moves both directions)

---

6. 📌 Bottom Line / Key Levels

$IXHL is showing signs of a short-term turnaround supported by fresh catalysts and a strong cash position.

The ~$75M cash balance, zero debt, and Fast Track status provide meaningful runway relative to current valuation.

Key levels to watch:

• Support: $3.00 area
• Momentum Confirmation: $3.50+
• Resistance: Near recent highs

This remains a high-risk, speculative biotech trade best suited for traders with high risk tolerance.

---

Disclaimer:

This content is for informational and educational purposes only and should not be considered financial advice. The author is not a licensed financial advisor.

All information presented is based on publicly available sources believed to be reliable but is not guaranteed for accuracy or completeness.

Investing in equities — especially micro-cap and biotechnology stocks — involves substantial risk, including the possible loss of principal. Price action can be highly volatile and unpredictable.

Readers should conduct their own due diligence (DYOR) and consult with a qualified financial professional before making any investment decisions.

The author may hold positions in securities mentioned and may buy or sell at any time without notice.